- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05141188
Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
Prevalence Of Extended Spectrum Beta Lactamase Producing Organisms In Urinary Tract Infections
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Urinary tract infection is among the most common nosocomial and community acquired infections. The Information on prevailing levels of antimicrobial resistance among common pathogens that associated with urinary tract infection is useful in making an appropriate choice of empiric therapy .
Resistance to antibiotic treatment in patients with urinary tract infections (UTIs) is a representative example of the increasing problem of antimicrobial resistance. Extended-spectrum β-lactamases (ESBLs) has emerged as an important mechanism of resistance in Gram-negative bacteria.
Bacterial production of extended-spectrum β-lactamases (ESBL) significantly reduces the efficacy of the most commonly used beta-lactam antibiotics for the empiric therapy of infections caused by putative Gram-negative .
Extended Spectrum Beta-Lactamase (ESBL) is derived from the mutated beta-lactamase enzyme, Beta-lactamase is an enzyme produced by bacteria that acts to inactivate beta-lactam class of antibiotics .
Extended Spectrum Beta-Lactamase is most commonly produced by the Enterobacteriaceae group, especially Escherichia coli and Klebsiella pneumonia.
ESBL-producing bacteria can also be resistant to the antibiotics class of aminoglycoside, fluoroquinolone, tetracycline, chloramphenicol, and sulfamethoxazole-trimethoprim.
The presence of ESBL-producing bacteria in an infection can result in treatment failure. Antibiotic resistance causes a decrease in the effectiveness of treatment, increases transmission of infection, increases mortality, and increases the cost of health care, while the discovery of new antibiotics is getting less and less
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studiecontact
- Naam: Mayada S Amin
- Telefoonnummer: 01098839535
- E-mail: maiada011200@med.sohag.edu.eg
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- This study will be conducted on a group of patients who are diagnosed that have urinary tract infections
Exclusion Criteria:
- The cases that do not give bacterial growth .
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
The aim of this study is to indicate the spread of extended spectrum beta lactamase producing gram negative bacteria ( that isolated from the urine of patients with urinary tract infections based on their susceptibility to antimicrobial agents )
Tijdsspanne: through study completion, an average of 1 year
|
This study will be conducted on a group of patients who are diagnosed that have urinary tract infections .
Antibiotic susceptibility will be examined on disk diffusion test on Mueller-Hinton agar (MHA) . The zones of growth inhibition around each of the antibiotic disks are measured to the nearest millimeter |
through study completion, an average of 1 year
|
The aim of this study is to indicate the spread of extended spectrum beta lactamase producing gram negative bacteria ( that isolated from the urine of patients with urinary tract infections based on their susceptibility to antimicrobial agents )
Tijdsspanne: through study completion, an average of 1 year
|
This study will be conducted on a group of patients who are diagnosed that have urinary tract infections .
Antibiotic susceptibility will be performed by automated method Vitek -2 system that measured by minimal inhibitory concentration (MIC) . |
through study completion, an average of 1 year
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Soh-Med-21-10-10
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .